Possible Consequences for the Pharma Industry if the USP Revision of the General Chapters 41 and 1251 is Enacted

Add bookmark

Possible Consequences for the Pharma Industry if the USP Revision of the General Chapters 41 and 1251 is Enacted

Add bookmark

Expected for a long time, USP has published a new draft to revise the General Chapters 41 “Balances” and 1251 “Weighing on an Analytical Balance” in the Pharmacopeial Forum PF 38(5) on September 4, 2012. One consequence of General Chapter 41 is the so-called minimum weight, which needs to be adhered to in order to fulfill applicable accuracy requirements for weighing systems.

It is very important to understand that the concept of minimum weight is not only restricted to applications in the scope of USP General Chapter 41, but applies to any weighing instrument - for balances in the laboratory and for scales in the production area.

In this podcast, learn from the GWP® weighing experts of METTLER TOLEDO and a USP expert panel member what the possible consequences for the pharmaceutical Industry are and what can be done to be prepared in an optimal way.

Listen to this brief podcast to:

  • Understand the consequences of possible changes of the USP revision of the General Chapters 41 and 1251
  • Learn how you can prepare yourself proactively
  • Hear what a possible solution might be

For more information, download our recently published GWP® White Paper to:

  • Understand the concept of minimum weight as the key to ensure consistently accurate weighing results in the laboratory and the production area
  • Learn how your specific weighing process requirements can be fulfilled and documented by a scientific strategy to select, calibrate and test your weighing systems
  • Get insights into the risk-based approach to performing routine testing of balances and scales
  • Learn about the proper weight selection for routine testing of balances and scales

Join our presentation about GWP® at the ISPE Annual Meeting on November 11 – 14, 2012, during session 206 "Innovation in Laboratory and Production Operations“. For further information, visit
http://www.ispe.org/2012-annual-meeting/innovation-laboratory-operations.

Have Your Say
Rate this feature and give us your feedback in the comments section below

Upcoming Events

Pharma Contract Manufacturing

23 - 25 March 2026

Mercure Hotel MOA Berlin, Germany

Pharma Contract Manufacturing

SmartLab Exchange USA

April 21 - 22, 2026

Philadelphia, USA

SmartLab Exchange USA

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended